$TWST

Cho Dennis sold $991K of TWST

Cho Dennis (See Remarks) sold 14,205 shares of Twist Bioscience Corp (TWST) at $69.75 ($0.99M total) on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cho Dennis
Published Jun 2, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information but no new operating/financial catalyst is stated.

02

Market read

Traders may treat the filing as a mild sentiment datapoint rather than a fundamental trigger.

03

What to watch

The article doesn’t state whether the sale was part of a broader planned schedule, tax-related liquidity, or diversification, limiting inference.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today; sale executed 2026-05-29

Background

SEC Form 4 reports insider transactions; this one is an officer/direct sale by Dennis Cho under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience officer Dennis Cho sold 14,205 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Limited/short-lived impact; any reaction is likely sentiment-driven rather than fundamental.

Evidence & confidence

The filing is an ownership-change disclosure (Form 4) with a pre-arranged 10b5-1 plan, reducing interpretability as a new negative catalyst.

Market effects

Minimal—this is company-specific insider activity without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with periods of weaker outlook; monitor for follow-on filings.

Key entities

  • Twist Bioscience Corp

    Subject of the insider transaction disclosure; officer Dennis Cho sold shares.

  • Dennis Cho

    Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.